Compare Quest Diagnostics Inc (DGX) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs SkyWest Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while SkyWest Inc trades at $96.52 (market cap $3.75B). The key difference: Quest Diagnostics Inc is far larger — about 6.8× SkyWest Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and SkyWest Inc for 8 Days on average.
| DGX | SKYW | |
|---|---|---|
Market Cap | $25.48B | $3.75B |
Volume | 941,866 | 196,324 |
Sector | Health | Industrials |
52-Week High | $247.45 | $115.94 |
52-Week Low | $173.49 | $78.40 |
Typical Hold Time | 56 Days | 8 Days |
Enterprise Value | $31.23B | $5.54B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
SkyWest (SKYW) trades at $96.52, down 0.12% with a bearish technical signal despite strong analyst support. The stock shows mixed earnings performance with Q1 2026 beating expectations but Q4 2025 and Q2 2026 missing estimates. Fundamentally, the company maintains solid profitability with 9.78% net margin and attractive valuation metrics including a P/E of 9.6. Recent news highlights fleet modernization efforts and expanding flying agreements while executives have been selling shares.
The outlook remains cautiously optimistic with a $112 consensus price target representing 16% upside potential. Key opportunities include fleet expansion and strong cash flow generation, while risks involve cost pressures and recent insider selling activity. The stock presents a value opportunity given its below-market valuation multiples and positive analyst coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
